Effects of drugs interfering with cholesterol homeostasis on tumor and tumor-infiltrating immune cells
| Drug . | Target . | Activity on tumor cells . | Activity on immune cells . |
|---|---|---|---|
| Statins (mevastatin, lovastatin, atorvastatin, fluvastatin, rosuvastatin, simvastatin) | HMGCR, Isoprenoid formation | Apoptosis of leukemic cells (AML) and myeloma cells (MM) | Blocking Rab5 prenylation leading to prolonged Ag presentation |
| ZAA | Squalene synthase | Apoptosis of leukemic cells (AML) | Increase CD11c+ DC activity, decrease of protumor neutrophils |
| T0901317 | LXR agonist | Apoptosis of leukemic cells (CLL and BPDCN) | |
| GW3965 | LXR agonist | Apoptosis of BPDCN cells | Expression of NK cell-activating ligands MICA and MICB and suppression of MDSCs |
| DDA | LXR partial agonist | Lethal autophagy of leukemic cells (AML) | Increased infiltration of CD3+ T cells and CD11c+ DCs |
| Avasimibe | ACAT-1 inhibitor | Suppression of leukemic cell proliferation (CML) | Enhanced TCR clustering and immunological synapse of CD8+ T cells |
| HDL-NP | Scavenger receptor type B-1 | Apoptosis of DLBCL cells | |
| SR9243 | LXR inverse agonist | Apoptosis of tumor cells | Increased CD11c+ DC and CD8+ T-cell activity |
| RGX-104 | LXRβ agonist | Suppression of MDSCs | |
| SULT2B1b | LXR antagonist | Increased CD11c+ DC activity, decrease in protumor neutrophils |
| Drug . | Target . | Activity on tumor cells . | Activity on immune cells . |
|---|---|---|---|
| Statins (mevastatin, lovastatin, atorvastatin, fluvastatin, rosuvastatin, simvastatin) | HMGCR, Isoprenoid formation | Apoptosis of leukemic cells (AML) and myeloma cells (MM) | Blocking Rab5 prenylation leading to prolonged Ag presentation |
| ZAA | Squalene synthase | Apoptosis of leukemic cells (AML) | Increase CD11c+ DC activity, decrease of protumor neutrophils |
| T0901317 | LXR agonist | Apoptosis of leukemic cells (CLL and BPDCN) | |
| GW3965 | LXR agonist | Apoptosis of BPDCN cells | Expression of NK cell-activating ligands MICA and MICB and suppression of MDSCs |
| DDA | LXR partial agonist | Lethal autophagy of leukemic cells (AML) | Increased infiltration of CD3+ T cells and CD11c+ DCs |
| Avasimibe | ACAT-1 inhibitor | Suppression of leukemic cell proliferation (CML) | Enhanced TCR clustering and immunological synapse of CD8+ T cells |
| HDL-NP | Scavenger receptor type B-1 | Apoptosis of DLBCL cells | |
| SR9243 | LXR inverse agonist | Apoptosis of tumor cells | Increased CD11c+ DC and CD8+ T-cell activity |
| RGX-104 | LXRβ agonist | Suppression of MDSCs | |
| SULT2B1b | LXR antagonist | Increased CD11c+ DC activity, decrease in protumor neutrophils |
Ag, antigen; MDSC, myeloid-derived suppressor cell.